Establishment of novel monoclonal antibodies KMab-1 and MMab-1 specific for IDH2 mutations

Biochemical and Biophysical Research Communications

Volumn 432, Issue 1, 2013, Pages 40-45

  Kaneko, Mika Kato ^a,b   Morita, Shunpei ^b   Tsujimoto, Yuta ^b   Yanagiya, Ryo ^b   Nasu, Kana ^b   Sasaki, Hiroko ^b   Hozumi, Yasukazu ^b   Goto, Kaoru ^b   Natsume, Atsushi ^c   Watanabe, Mika ^a   Kumabe, Toshihiro ^a   Takano, Shingo ^d   Kato, Yukinari ^a,b  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b YAMAGATA UNIVERSITY   (Japan)

^c NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

IDH2 mutation; Monoclonal antibody; R172K; R172M

Indexed keywords

ENZYME ANTIBODY; ISOCITRATE DEHYDROGENASE 2; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY KMAB 1; MONOCLONAL ANTIBODY MMAB 1; MUTANT PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ANTIBODY SCREENING; ANTIGEN SPECIFICITY; ARTICLE; CELL FUSION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLIOMA; IMMUNIZATION; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RAT; WESTERN BLOTTING; WILD TYPE;

ANIMALS; ANTIBODIES, MONOCLONAL; CHO CELLS; CRICETINAE; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLIOMA; ISOCITRATE DEHYDROGENASE; MICE; MUTATION; RATS;

MUS; RATTUS;

EID: 84875368172     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.01.088     Document Type: Article

References (20)

1. Parsons D.W., Jones S., Zhang X., Lin J.C., Leary R.J., Angenendt P., Mankoo P., Carter H., Siu I.M., Gallia G.L., Olivi A., McLendon R., Rasheed B.A., Keir S., Nikolskaya T., Nikolsky Y., Busam D.A., Tekleab H., Diaz L.A., Hartigan J., Smith D.R., Strausberg R.L., Marie S.K., Shinjo S.M., Yan H., Riggins G.J., Bigner D.D., Karchin R., Papadopoulos N., Parmigiani G., Vogelstein B., Velculescu V.E., Kinzler K.W. An integrated genomic analysis of human glioblastoma multiforme. Science 2008, 321:1807-1812.
2. Yan H., Parsons D.W., Jin G., McLendon R., Rasheed B.A., Yuan W., Kos I., Batinic-Haberle I., Jones S., Riggins G.J., Friedman H., Friedman A., Reardon D., Herndon J., Kinzler K.W., Velculescu V.E., Vogelstein B., Bigner D.D. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 2009, 360:765-773.
3. Sonoda Y., Kumabe T., Nakamura T., Saito R., Kanamori M., Yamashita Y., Suzuki H., Tominaga T. Analysis of IDH1 and IDH2 mutations in Japanese glioma patients. Cancer sci. 2009, 100:1996-1998.
4. Balss J., Meyer J., Mueller W., Korshunov A., Hartmann C., von Deimling A. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol. 2008, 116:597-602.
5. Pansuriya T.C., van Eijk R., d'Adamo P., van Ruler M.A., Kuijjer M.L., Oosting J., Cleton-Jansen A.M., van Oosterwijk J.G., Verbeke S.L., Meijer D., van Wezel T., Nord K.H., Sangiorgi L., Toker B., Liegl-Atzwanger B., San-Julian M., Sciot R., Limaye N., Kindblom L.G., Daugaard S., Godfraind C., Boon L.M., Vikkula M., Kurek K.C., Szuhai K., French P.J., Bovee J.V. Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome. Nat. Genet. 2011, 43:1256-1261.
6. Amary M.F., Damato S., Halai D., Eskandarpour M., Berisha F., Bonar F., McCarthy S., Fantin V.R., Straley K.S., Lobo S., Aston W., Green C.L., Gale R.E., Tirabosco R., Futreal A., Campbell P., Presneau N., Flanagan A.M. Ollier disease and Maffucci syndrome are caused by somatic mosaic mutations of IDH1 and IDH2. Nat. Genet. 2011, 43:1262-1265.
7. Amary M.F., Bacsi K., Maggiani F., Damato S., Halai D., Berisha F., Pollock R., O'Donnell P., Grigoriadis A., Diss T., Eskandarpour M., Presneau N., Hogendoorn P.C., Futreal A., Tirabosco R., Flanagan A.M. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J. Pathol. 2011, 224:334-343.
8. Ward P.S., Patel J., Wise D.R., Abdel-Wahab O., Bennett B.D., Coller H.A., Cross J.R., Fantin V.R., Hedvat C.V., Perl A.E., Rabinowitz J.D., Carroll M., Su S.M., Sharp K.A., Levine R.L., Thompson C.B. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer cell 2010, 17:225-234.
9. Chotirat S., Thongnoppakhun W., Promsuwicha O., Boonthimat C., Auewarakul C.U. Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients. J. Hematol. Oncol. 2012, 5:5.
10. Dang L., White D.W., Gross S., Bennett B.D., Bittinger M.A., Driggers E.M., Fantin V.R., Jang H.G., Jin S., Keenan M.C., Marks K.M., Prins R.M., Ward P.S., Yen K.E., Liau L.M., Rabinowitz J.D., Cantley L.C., Thompson C.B., Vander Heiden M.G., Su S.M. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009, 462:739-744.
11. Takano S., Kato Y., Yamamoto T., Kaneko M.K., Ishikawa E., Tsujimoto Y., Matsuda M., Nakai K., Yanagiya R., Morita S., Tsuboi K., Matsumura A. Immunohistochemical detection of IDH1 mutation, p53, and internexin as prognostic factors of glial tumors. J. Neurooncol. 2012, 108:361-373.
12. Takano S., Tian W., Matsuda M., Yamamoto T., Ishikawa E., Kaneko M.K., Yamazaki K., Kato Y., Matsumura A. Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry and sequencing. Brain Tumor Pathol. 2011, 28:115-123.
13. Kaneko M.K., Tian W., Takano S., Suzuki H., Sawa Y., Hozumi Y., Goto K., Yamazaki K., Kitanaka C., Kato Y. Establishment of a novel monoclonal antibody SMab-1 specific for IDH1-R132S mutation. Biochem. Biophys. Res. Commun. 2011, 406:608-613.
14. R132H, the most common glioma-derived mutation. Biochem. Biophys. Res. Commun. 2009, 390:547-551.
15. Capper D., Zentgraf H., Balss J., Hartmann C., von Deimling A. Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathol. 2009, 118:599-601.
16. Sakaguchi N., Miyamoto Y., Yoneda Y., Ogino K., Tachibana T. Generation of a rat monoclonal antibody specific for importin alpha3/Qip1. Hybrid. Hybridomics 2003, 22:397-400.
17. Kato Y., Kaneko M.K., Kuno A., Uchiyama N., Amano K., Chiba Y., Hasegawa Y., Hirabayashi J., Narimatsu H., Mishima K., Osawa M. Inhibition of tumor cell-induced platelet aggregation using a novel anti-podoplanin antibody reacting with its platelet-aggregation-stimulating domain. Biochem. Biophys. Res. Commun. 2006, 349:1301-1307.
18. Zhao S., Lin Y., Xu W., Jiang W., Zha Z., Wang P., Yu W., Li Z., Gong L., Peng Y., Ding J., Lei Q., Guan K.L., Xiong Y. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science 2009, 324:261-265.
19. Hartmann C., Meyer J., Balss J., Capper D., Mueller W., Christians A., Felsberg J., Wolter M., Mawrin C., Wick W., Weller M., Herold-Mende C., Unterberg A., Jeuken J.W., Wesseling P., Reifenberger G., von Deimling A. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1010 diffuse gliomas. Acta Neuropathol. 2009, 118:469-474.
20. Kaneko M.K., Kunita A., Abe S., Tsujimoto Y., Fukayama M., Goto K., Sawa Y., Nishioka Y., Kato Y. Chimeric anti-podoplanin antibody suppresses tumor metastasis through neutralization and antibody-dependent cellular cytotoxicity. Cancer Sci. 2012, 103:1913-1919.